Identification
Name Bitolterol
Accession Number DB00901 (APRD00827)
Type small molecule
Description Bitolterol mesylate is a beta-2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001. [Wikipedia]
Structure
Categories (*)
Molecular Weight 461.5494
Groups withdrawn
Monoisotopic Weight 461.220223107
Pharmacology
Indication Used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation. It is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Mechanism of action Bitolterol is an adrenergic beta-2 agonist. Asthma results from a narrowing of the bronchial tubes. This narrowing is caused by muscle spasm and inflammation within the bronchial tubes. Agonism of the beta-2 adrenergic receptors by bitolterol leads to a relaxation of the smooth muscles surrounding these airway tubes which then increases the diameter and ease of air flow through the tubes.
Absorption Not Available
Protein binding Not Available
Biotransformation Not Available
Route of elimination Not Available
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Entacapone Entacapone may increase the effect and toxicity of bitolterol.
Food Interactions Not Available
Beta-2 adrenergic receptor
Name Beta-2 adrenergic receptor
Gene Name ADRB2
Pharmacological action yes
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Wilson AJ, Gibson PG, Coughlan J: Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev. 2000;(2):CD001281. - Pubmed
  • Friedel HA, Brogden RN: Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs. 1988 Jan;35(1):22-41. - Pubmed
DTHybrid score 0.4603
Id Partner name Gene Name Score
193 Beta-1 adrenergic receptor ADRB1 0.2195
1517 Beta-3 adrenergic receptor ADRB3 0.0648
4119 Cytochrome P450 2D6 CYP2D6 0.0544
556 Alpha-1A adrenergic receptor ADRA1A 0.0293
3923 Cholinesterase BCHE 0.028
320 5-hydroxytryptamine 1A receptor HTR1A 0.0245
1588 Multidrug resistance protein 1 ABCB1 0.0209
4512 Cytochrome P450 3A4 CYP3A4 0.0204
2300 Lysozyme E 0.0191
3633 Lysozyme R 0.0191
5597 Lysozyme 17 0.0191
318 Alpha-2A adrenergic receptor ADRA2A 0.0186
6144 Solute carrier family 22 member 2 SLC22A2 0.0169
6040 6-phosphogluconate dehydrogenase, decarboxylating PGD 0.016
6016 Cytochrome P450 2C19 CYP2C19 0.0147
885 5-hydroxytryptamine 1B receptor HTR1B 0.0137
4200 Cytochrome P450 1A2 CYP1A2 0.0125
629 Alpha-2B adrenergic receptor ADRA2B 0.0113
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0109
3810 Catechol O-methyltransferase COMT 0.0101
632 Alpha-1B adrenergic receptor ADRA1B 0.01
6145 Solute carrier family 22 member 1 SLC22A1 0.01
378 Alpha-2C adrenergic receptor ADRA2C 0.0096
5718 Cytochrome P450 2A6 CYP2A6 0.0094
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0089
4757 Cytochrome P450 2C9 CYP2C9 0.0088
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0086
6024 Cytochrome P450 1A1 CYP1A1 0.0081
1820 Beta-nerve growth factor NGF 0.0081
4146 Phosphatidylinositol 3-kinase regulatory subunit gamma PIK3R3 0.0074
4145 Phosphatidylinositol 3-kinase regulatory subunit beta PIK3R2 0.0074
828 Phenylalanine-4-hydroxylase PAH 0.0071
3109 Phenylalanine-4-hydroxylase phhA 0.0071
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0063
1281 Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 0.006
789 Alpha-1D adrenergic receptor ADRA1D 0.0057
824 Sodium-dependent serotonin transporter SLC6A4 0.0057
777 Tumor necrosis factor TNF 0.0054
6107 Cytochrome P450 3A7 CYP3A7 0.0051
713 Sodium-dependent dopamine transporter SLC6A3 0.0051
3941 Amine oxidase [flavin-containing] A MAOA 0.0051
6147 Solute carrier family 22 member 3 SLC22A3 0.005
4118 Cytochrome P450 3A5 CYP3A5 0.0049
1176 Mitogen-activated protein kinase 1 MAPK1 0.004
118 Organic cation/carnitine transporter 2 SLC22A5 0.0038
4924 Cytochrome P450 2C8 CYP2C8 0.0036
1374 Natriuretic peptides B NPPB 0.0029
6164 POU domain, class 5, transcription factor 1 POU5F1 0.0029
1827 Gap junction alpha-1 protein GJA1 0.0029
1908 Vascular cell adhesion protein 1 VCAM1 0.0029
131 Synaptic vesicular amine transporter SLC18A2 0.0028
465 Calmodulin CALM1 0.0028
3876 Aromatic-L-amino-acid decarboxylase DDC 0.0026
194 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 0.0024
183 Vascular endothelial growth factor A VEGFA 0.0022
3939 Amine oxidase [flavin-containing] B MAOB 0.0022
6151 Monocarboxylate transporter 10 SLC16A10 0.0019
1360 Sphingomyelin phosphodiesterase SMPD1 0.0018
6013 Cytochrome P450 2E1 CYP2E1 0.0018
502 5-hydroxytryptamine 2A receptor HTR2A 0.0017
492 Histamine H1 receptor HRH1 0.0017
3947 Xanthine dehydrogenase/oxidase XDH 0.0015
1256 5-hydroxytryptamine 6 receptor HTR6 0.0015
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.0014
124 Histamine H2 receptor HRH2 0.0013
716 5-hydroxytryptamine 7 receptor HTR7 0.0013
6432 Transporter snf 0.0013
436 5-hydroxytryptamine 2B receptor HTR2B 0.0012
432 D(4) dopamine receptor DRD4 0.0012
638 D(3) dopamine receptor DRD3 0.0012
20 Prostaglandin G/H synthase 1 PTGS1 0.0012
590 5-hydroxytryptamine 2C receptor HTR2C 0.0011
23 D(1A) dopamine receptor DRD1 0.001
831 D(2) dopamine receptor DRD2 0.001
6106 Cytochrome P450 2C18 CYP2C18 0.0009
274 Muscarinic acetylcholine receptor M5 CHRM5 0.0009
833 Organic cation/carnitine transporter 1 SLC22A4 0.0009
450 Muscarinic acetylcholine receptor M4 CHRM4 0.0009
51 Muscarinic acetylcholine receptor M3 CHRM3 0.0008
617 Muscarinic acetylcholine receptor M2 CHRM2 0.0008
103 Muscarinic acetylcholine receptor M1 CHRM1 0.0007
6030 Cytochrome P450 2B6 CYP2B6 0.0007